Company intelligence

MBRX

Moleculin Biotech, Inc. · NASDAQ · Healthcare

Price$0.60-1.80% · −$0.01

Market cap3.2MEquity value

P / E-0.0Trailing ratio

Volume454.05KLatest session

Market data

MBRX price chart

TradingView

Related signals

1 min delayed

Browse public MBRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

MBRXJun 30, 2026-0.37% since signal

Moleculin's Annamycin shows AML remission signals; trial to proceed

New MIRACLE trial data show Annamycin arms achieved higher CRc after one cycle (50% and 57%) versus 29% control in relapsed/refractory AML. The Independent Data Monitoring Committee recommended keeping both doses and continuing the trial, with significance expected only at the final analysis under the O’Brien-Fleming design. Moleculin Biotech stock dropped about 26% on the news.

View signal analysis

MBRXMay 13, 2026-1.79% since signal

Moleculin Biotech's Annamycin Shows Promising Efficacy Amid Stock Declines

Moleculin Biotech's preliminary results from the MIRACLE study reveal promising remission rates exceeding 40% for Annamycin combined with cytarabine, compared to historical rates. Despite this, the stock's recent decline of over 32% year-to-date may present a buying opportunity for investors anticipating further positive updates as enrollment continues through 2026.

View signal analysis

Research